Your session is about to expire
← Back to Search
Histone Deacetylase Inhibitor
HBI-8000 + Pembrolizumab for Non-Small Cell Lung Cancer (HBI-8000 Trial)
Phase 2
Waitlist Available
Research Sponsored by HUYABIO International, LLC.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 38 months
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a combination of two drugs, HBI-8000 and pembrolizumab, for patients with advanced lung cancer. The treatment aims to make cancer cells more vulnerable and boost the immune system to fight the cancer.
Eligible Conditions
- Non-Small Cell Lung Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 38 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~38 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Objective response rate (ORR)
Secondary study objectives
Disease Control Rate (DCR)
Duration of response (DoR)
Progression-Free Survival (PFS)
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: HBI-8000 in combination with pembrolizumabExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
HUYABIO International, LLC.Lead Sponsor
11 Previous Clinical Trials
959 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have had fluid build-up in your chest that needed to be drained multiple times within the past 3 months, except if you have a special device called a PleurX™ port.You have a current or past lung condition that caused inflammation and required treatment with steroids.
Research Study Groups:
This trial has the following groups:- Group 1: HBI-8000 in combination with pembrolizumab
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger